- InvestInvestment SuiteExclusiveFeatures
- PlatformProduct SuiteFeatures and ToolsCalculatorsPricing
- ResearchResearch CallsResearch Reports
- MarketStocksIndicesMutual FundsIPO
- LearnResourceInvesting GuideEvents
- Partner
- Support
Invest
Platform
Research
Market
Learn
Compare Nippon India Pharma Fund vs LIC MF Healthcare Fund
Fund Comparison
Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Fund Details
Risk | Very High | Very High |
Rating | 3.0 | 1.0 |
Min SIP Amount | ₹100 | ₹200 |
Expense Ratio | 1.81 | 2.44 |
NAV | ₹524.96 | ₹30.45 |
Fund Started | 10 May 2004 | 08 Feb 2019 |
Fund Size | ₹8638.23 Cr | ₹84.15 Cr |
Exit Load | Exit load of 1% if redeemed within 1 month. | Exit Load for units in excess of 12% of the investment,1% will be charged for redemption within 90 days. |
Risk
Very High
Very High
Rating
3.0
1.0
Min SIP Amount
₹100
₹200
Expense Ratio
1.81
2.44
NAV
₹524.96
₹30.45
Fund Started
10 May 2004
08 Feb 2019
Fund Size
₹8638.23 Cr
₹84.15 Cr
Exit Load
Exit load of 1% if redeemed within 1 month.
Exit Load for units in excess of 12% of the investment,1% will be charged for redemption within 90 days.
Returns
1 Year | 33.29% | 41.15% |
3 Year | 19.13% | 16.75% |
5 Year | 28.04% | 23.30% |
1 Year
33.29%
41.15%
3 Year
19.13%
16.75%
5 Year
28.04%
23.30%
Holding Analysis
Equity | 96.97% | 95.82% |
Cash | 3.03% | 4.18% |
Equity
96.97%
95.82%
Cash
3.03%
4.18%
Top Holdings
Top 10 Holdings |
|
|
Top 10 Holdings
Name | Assets |
|---|---|
Sun Pharmaceutical Industries Ltd. | 13.52% |
Divi's Laboratories Ltd. | 9.65% |
Lupin Ltd. | 7.61% |
Cipla Ltd. | 5.50% |
Apollo Hospitals Enterprise Ltd. | 5.13% |
Dr. Reddy's Laboratories Ltd. | 5.10% |
Vijaya Diagnostic Centre Ltd. | 4.09% |
Ajanta Pharma Ltd. | 3.36% |
Medplus Health Services Ltd. | 3.23% |
Gland Pharma Ltd. | 3.02% |
Name | Assets |
|---|---|
Sun Pharmaceutical Industries Ltd. | 9.87% |
Piramal Pharma Ltd. | 7.26% |
Artemis Medicare Services Ltd. | 6.66% |
Torrent Pharmaceuticals Ltd. | 5.35% |
Syngene International Ltd. | 4.54% |
Glenmark Pharmaceuticals Ltd. | 4.47% |
Mankind Pharma Ltd. | 4.32% |
Neuland Laboratories Ltd. | 4.24% |
Cipla Ltd. | 4.19% |
Suven Pharmaceuticals Ltd. | 4.08% |
Fund Manager
Name | Akshay Sharma | Karan Doshi |
Start Date | 01 Dec 2022 | 31 Jul 2023 |
Name
Akshay Sharma
Karan Doshi
Start Date
01 Dec 2022
31 Jul 2023
About Fund
Description | The scheme seeks to generate consistent returns by investing in equity / equity related or fixed income securities of pharma and other associated companies. | The Scheme seeks to achieve long term capital appreciation by predominantly investing in equity and equity related instruments of companies engaged in Healthcare and Allied sectors. |
Launch Date | 10 May 2004 | 08 Feb 2019 |
Description
The scheme seeks to generate consistent returns by investing in equity / equity related or fixed income securities of pharma and other associated companies.
The Scheme seeks to achieve long term capital appreciation by predominantly investing in equity and equity related instruments of companies engaged in Healthcare and Allied sectors.
Launch Date
10 May 2004
08 Feb 2019
